Financiere des Professionnels Fonds d investissement inc. Has $21.11 Million Stock Position in Becton, Dickinson and Company $BDX

03 Jan 2026, 14:02 by Sarita Garza · The Markets Daily

Financiere des Professionnels Fonds d investissement inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 11.3% during the third quarter, Holdings Channel reports. The firm owned 112,760 shares of the medical instruments supplier’s stock after acquiring an additional 11,427 shares during the period. Becton, Dickinson and Company makes up approximately 1.2% of Financiere des Professionnels Fonds d investissement inc.’s investment portfolio, making the stock its 14th biggest position. Financiere des Professionnels Fonds d investissement inc.’s holdings in Becton, Dickinson and Company were worth $21,105,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SOA Wealth Advisors LLC. increased its holdings in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the period. Bell Investment Advisors Inc lifted its holdings in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares during the period. Bank of Jackson Hole Trust boosted its position in shares of Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 95 shares in the last quarter. CVA Family Office LLC increased its stake in Becton, Dickinson and Company by 79.5% in the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 97 shares during the last quarter. Finally, CoreFirst Bank & Trust acquired a new position in Becton, Dickinson and Company during the second quarter valued at approximately $38,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $194.73 on Friday. The stock has a market cap of $55.48 billion, a price-to-earnings ratio of 33.40, a P/E/G ratio of 1.79 and a beta of 0.23. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The company’s fifty day moving average is $191.03 and its 200 day moving average is $186.94. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a dividend of $1.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research analyst reports. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Morgan Stanley lifted their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Piper Sandler dropped their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Jefferies Financial Group lifted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $205.64.

Read Our Latest Stock Report on BDX

Insider Activity at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the sale, the executive vice president directly owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,052 shares of company stock valued at $201,235. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.